v3.26.1
Shareholders’ equity
 3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Shareholders' equity Shareholders’ equity
The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2025:
Number of
Shares		Weighted-
Average Exercise
Price 
Outstanding as of December 31, 202524,089,219$1.07 
Granted–– 
Exercised(825,281)0.22 
Forfeited–– 
Outstanding as of March 31, 202623,263,938$1.10 
Options exercisable as of March 31, 202623,263,938$1.10 
The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2025:
Number of
Shares		Weighted-
Average Exercise
Price
Outstanding as of December 31, 202536,376,041$7.38 
Granted10,103,5583.43 
Exercised(103,287)2.99 
Forfeited(640,277)5.73 
Outstanding as of March 31, 202645,736,035$6.54 
Options exercisable as of March 31, 202620,191,253$9.82 
The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2025:
Number of
Shares		Weighted-
Average Grant
Date Fair Value
Outstanding as of December 31, 20258,837,384$4.75 
Granted4,055,2813.43 
Vested and settled(2,416,303)5.51 
Forfeited(335,734)4.72 
Outstanding as of March 31, 202610,140,628$4.04 
As of March 31, 2026, the number of shares available for issuance under the 2020 Plan was 33,758,986, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.
Stock-based compensation:
Stock-based compensation was classified in the condensed consolidated statements of loss and comprehensive loss as follows:
Three months ended March 31,
20252026
Research and development expenses$8,136 $7,039 
Sales, general, and administrative expenses6,650 4,974 
 $14,786 $12,013